Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Content Provider	Europe PMC
Author	Beckers, Henny JM Schouten, Jan SAG Webers, Carroll AB
Abstract	Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment of open-angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety profile, with an incidence of ocular burning and stinging <5%. Published data show that brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for lowering intraocular pressure (IOP). There is some evidence that brinzolamide/timolol may be more comfortable. Although patients receiving brinzolamide/timolol may experience more blurred vision on instillation, some data show a preference for brinzolamide/timolol over dorzolamide/timolol. Although available data to assess the role of brinzolamide/timolol in daily clinical practice are still limited, these first results suggest the agent to be a reasonable alternative for patients who do not reach target IOP with monotherapy.
ISSN	11775467
Volume Number	3
PubMed Central reference number	PMC2773281
PubMed reference number	19898664
Journal	Clinical Ophthalmology (Auckland, N.Z.) [Clin Ophthalmol]
e-ISSN	11775483
Language	English
Publisher	Dove Medical Press
Publisher Date	2009-11-02
Access Restriction	Open
Rights License	This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. © 2009 Beckers et al, publisher and licensee Dove Medical Press Ltd.
Subject Keyword	brinzolamide dorzolamide fixed combination glaucoma IOP timolol
Content Type	Text
Resource Type	Article
Subject	Ophthalmology